BIFIDO Co., Ltd. (KOSDAQ:238200)
South Korea · Delayed Price · Currency is KRW 3,020.00
-50.00 (-1.63%)
At close: Jan 23, 2026
BIFIDO Revenue
BIFIDO had revenue of 3.71B KRW in the quarter ending September 30, 2025, with 56.95% growth. This brings the company's revenue in the last twelve months to 18.65B, up 40.89% year-over-year. In the year 2024, BIFIDO had annual revenue of 12.35B, down -33.72%.
Revenue (ttm)
18.65B
Revenue Growth
+40.89%
P/S Ratio
1.32
Revenue / Employee
224.67M
Employees
83
Market Cap
24.70B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 12.35B | -6.28B | -33.72% |
| Dec 31, 2023 | 18.63B | 4.06B | 27.82% |
| Dec 31, 2022 | 14.58B | 2.46B | 20.32% |
| Dec 31, 2021 | 12.12B | -264.16M | -2.13% |
| Dec 31, 2020 | 12.38B | -631.81M | -4.86% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Hurum | 95.37B |
| GeneBioTech Co. ,Ltd | 92.28B |
| ChoA Pharmaceutical Co., LTD. | 60.50B |
| WooGene B&G | 54.77B |
| Seoul Pharma | 52.43B |
| Union Korea Pharm | 33.83B |
| Daesung Microbiological Labs. | 25.86B |
| HLscience | 18.10B |